FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

|--|

hours per response:

OMB Number: 3235-0287 Estimated average burden

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					oi occi	11011 30(11)	or tire	invesiment C	ompany Act	01 1340							
1. Name and Address of Reporting Person*  Amello Jason						2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ ZIOP ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
7 HIIICHO	<del>) 503011</del>											Director		10% O	-		
													(give title	Other (: below)	specify		
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 12/31/2012							Execut	ive Vice Pr	esident & CI	O		
C/O ZIOPHARM ONCOLOGY, INC.						12/01/2012											
ONE FIRST AVENUE, BLDG.3																	
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)											Line		ll		_		
BOSTON MA 02129			02129								1 2	_	, ,				
												Form fil Person		han One Repo	ting		
(City)	(S	tate)	(Zip)									. 0.00					
(0.1.9)	(0		(=.p)														
		Ta	ble I - Non-D	) erivati	ve Se	ecurities	s Ac	quired, Di	sposed o	of, or Be	neficially	<b>Owned</b>					
11				Transaction ate Ionth/Day/	2A. Deemed Execution Date if any (Month/Day/Yea		r, Transaction Disposed Code (Instr.		ities Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and 5	Beneficia Owned F	s Form		7. Nature of Indirect Beneficial Ownership			
						,		Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																
			(e.	g., puts	s, cai	ıs, warr	ants	s, options,	converti	bie seci	irities)						
1. Title of 2. Derivative Security (Instr. 3) Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code (	Transaction Code (Instr.		er of e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Employee Stock Option (right to	\$4.16	12/31/2012		A		150,000		(1)	12/31/2022	Common Stock	150,000	\$0.00	150,000	D			

## **Explanation of Responses:**

1. 50,000 shares vest on 12/31/2013, 12/31/2014 and 12/31/2015.

## Remarks:

/s/ Jason A. Amelllo

01/03/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.